The pressure is mounting on Roche after Swiss rival Sandoz filed a US biosimilar of cancer and inflammatory diseases drug rituximab, closely behind a rival from Teva and Celltrion. Rituxan ...

Roche has presented new data which shows Gazyva is superior to its established Rixtuxan/Mabthera in treating follicular lymphoma (FL). Rituxan/MabThera is one of Roche's biggest sellers ...

Rituximab, developed in partnership by Roche and Biogen Idec, was the first anti-CD20 monoclonal antibody to be approved for the treatment of non-Hodgkin lymphomas. It works by specifically ...

Monday, Roche Holdings AG (OTC:RHHBY) announced topline data from Phase 3 STARGLO study of Columvi (glofitamab) in ...

After collecting a handful of oncology approvals since its first leukemia nod in 2013, Roche’s Biogen-partnered Rituxan successor, Gazyva, is chasing new horizons in active lupus nephritis.

Roche has released data from the Phase III STARGLO ... the safety and efficacy of Columvi plus GemOx against MabThera/Rituxan (rituximab) with GemOx. The trial participants had received a minimum ...

Roche is rolling out what it describes as a new type of infectious disease diagnostic in Europe, with a single test capable of screening for up to 12 of the most common respiratory viruses at once ...

While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious complication of systemic lupus ...

Mehta A, Popplewell L, Collins GP, et al. Magrolimab plus rituximab in relapsed/refractory indolent non-hodgkin lymphoma: phase 1/2 trial 3-year follow-up. Blood Adv . Published online August 30 ...

Basel, 26 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the phase III REGENCY study of Gazyva®/Gazyvaro® (obinutuzumab) in people with active ...

Roche ROG-0.56%decrease; red down pointing triangle Holding is narrowing the diseases it targets with its pharmaceutical research and development activities, betting on a slimmed-down approach as ...

Patients on abatacept and rituximab had about the same rate of ... Novartis, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB.